TPST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempest Therapeutics Inc (TPST) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is currently in a bearish technical trend, and while there are positive insider buying signals and strategic moves to extend its cash runway, the company's financial performance is weak, and the stock lacks strong trading signals or immediate catalysts for significant upward momentum.
The stock is in a bearish trend with the MACD histogram below 0 and negatively expanding. RSI at 16.536 indicates the stock is oversold, but the moving averages (SMA_200 > SMA_20 > SMA_5) confirm a bearish setup. The stock is trading near its support level of 1.74, with resistance at 2.01.
Insider buying by the CEO, which is generally viewed as a positive signal.
Strategic acquisition of Factor Bioscience's CAR-T programs, extending the cash runway into 2027 and expanding the pipeline.
Potential for short-term price increases based on historical candlestick pattern analysis.
Weak financial performance with a significant decline in net income (-66.74% YoY) and EPS (-85.15% YoY).
Recent stock price volatility due to financing announcements and dilution concerns.
Lack of significant hedge fund or insider trading trends.
The company's financials for Q3 2025 show no revenue growth (0% YoY), a significant drop in net income to -$3.51 million (-66.74% YoY), and a sharp decline in EPS to -0.79 (-85.15% YoY). Gross margin remains at 0%, indicating no profitability.
H.C. Wainwright recently upgraded the stock to Buy with an $11 price target, citing the strategic acquisition of CAR-T programs and the company's renewed focus. However, this is based on long-term potential rather than immediate performance.
